• 
• 

• A
• A
• A

Bone Marrow Transplantation

“Open-label, randomized comparison of dolasetron versus ondansetron for prevention of nausea and vomiting during high-dose chemotherapy and stem cell transplantation”. R. Mandanas, R. Beveridge, R. Rifkin, H. Wallace, A. Greenspan, G. Spitzer, H. Guo, L. Asmar. Poster presentation at ASBMT, February, 2004.

“Sequential IL-3 and GM-CSF Therapy in Bone Marrow Failure with Long-Term Follow-Up of Responses.” Wu, HH, Talpaz, M., Champlin, R. et al (2003), Cancer 98, 2410-2419.

“Sequential IL-3 and GM-CSF Therapy in Bone Marrow Failure with Long-Term Follow-Up of Responses.” Wu, HH, Talpaz, M., Champlin, R. et al. Presented at 39th Annual Meeting of ASCO, May 2003.

“Incapacitating peripheral neuropathy as a manifestation of chronic graft-versus-host disease”. Greenspan A, Deeg HJ, Cottler-Fox M, Sirdofski M, Spitzer TR, Kattah J. Bone Marrow Transplant 1990: 5:349-352.

“Escalating doses of VP-16 with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation”. Spitzer TR, Cottler-Fox M, Torrisi J, Cahill R, Greenspan A, Lynch M, Deeg HJ. Bone Marrow Transplant 1989: 4:559-565.

“Matched pair analysis of hematopoietic progenitor cell mobilization using G-CSF (G) versus cyclophosphamide, VP-16 and G-CSF (CVG): CVG enhancements of CD 34+ cell collections are not necessarily cost-effective”. LP Akard, JM Thompson, MJ Dugan, M Wiemann, A Greenspan, S Hanks, M Swinney, A Nyhuis and J Jansen. Presented at the American Society of Hematology annual meeting, 1998.

Breast Cancer

“Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer”. S.A. Jones, J. Cantrell, T. Whittaker, J. Pippen, L. Asmar, J.A. Blum. Journal of Clinical Oncology. 2007 (Submitted for publication.)

“Phase II Randomized, Open-Label Trial of Weekly Paclitaxel versus Weekly Paclitaxel and Carboplatin as First Line Therapy for Metastatic Breast Cancer, Including Patients Who Have Relapsed From Prior Taxane Therapy”. Robert N, Loesch D, Lindquist D, Ratnam S, Hyman W, Whittaker T, Logie K, Favret A, legbodu D, Asmar L. Submitted to Journal of Clinical Oncology.

“Phase II Randomized, Open-Label Trial of Weekly Paclitaxel versus Weekly Paclitaxel and Carboplatin as First Line Therapy for Metastatic Breast Cancer, Including Patients Who Have Relapsed From Prior Taxane Therapy”. Robert N, Loesch D, Lindquist D, Ratnam S, Hyman W, Whittaker T, Logie K, Favret A, legbodu D, Asmar L. Submitted to Journal of Clinical Oncology.

“The Relationship of Radiation Pneumonitis to Treated Lung Volume in Breast Conservations Therapy” Minor GI, Yashar CM, Spanos WJ Jr, Jose BO, Silverman CL, Carrascosa LA, Farmer M, Paris KJ. Breast J. 2006 Jan-Feb; 12(1):48-52

“Postmastectomy Chest Wall Radiation with Electron-Beam Therapy: Outcomes and Complications at the University of Louisville.” Minor, GI. Cancer J. 2005 May-June; 11(3):204-208

“Cutaneous Angiosarcoma Following Breast-conserving Surgery and Radiation”. Steven Billings, MD, Jesse McKenney, MD, Andrew Folpe, MD, Michael Hardacre, MD, and Sharon Weiss, MD. Am J Surg Pathol 2004; 28 (6): 781-788.

“A Phase II Trial of Weekly Taxol, 5-Flourouracil and Leucovorin Regimen in Patients with Metastatic Breast Cancer”. Loesch, D.M, N. Robert, L. Dakhil, G. Gusfey, J.Hopkins, T.Rohrbaugh. American Oncology Resources, TX. USA. Breast Cancer Research, Jan 2003.

”A Phase II Trial of Weekly Taxol and Weekly Carboplatin in Patients with Metastatic Breast Cancer”. Loesch D.M., et al, USONCOLOGY, Houston, TX,USA. Journal of Clinical Oncology. Sept 15, 2002.

“Cardiovascular safety of doxorubicin (A) + cyclophosphamide (C) followed by paclitaxel (P) (every three weeks for 4 cycles) versus doxorubicin + paclitaxel followed by weekly paclitaxel in a phase III adjucant trial of high risk breast cancer”. D.M. Loesch, F.A. Greco, M. Khan, S.J. Vukelja, J. O’Shaughnessy, M. Modiano, N. Robert, L.Asmar.: USONCOLOGY, Houston, TX, USA. Poster, ASCO, Abstract#255, 2002.

.“Efficiacy and tolerability of a weekly Taxol (T) plus Carboplatin (C) regimen in patients<65 years versus>or equal to 65 years with advanced breast cancer (ABC)”. M. O’Rourke, D. Loesch, N. Robert, E. Cox, G. Roppolo, L. Asmar: USONCOLOGY, Houston, TX,USA. Poster, ASCO, Abstract #1967, 2002.

“A Phase II Trial of Weekly Taxol and Carboplatin in Metastic Breast Cancer”. D. Loesch, N. Robert, et al, USONCOLOGY, Houston, TX, USA. Poster, ASCO, Abstract# , 2000.

“Randomized Pilot Trial of Taxotere (T) and Doxorubicin (D) As Primary Chemotherapy for Breast Cancer”. K.D. Miller, W. McCaskill-Stevens, J. Sisk, D.M. Loesch, and G. W. Sledge, Jr., Indiana University, Indianapolis, Indiana, Hoosier Oncology Group. Poster, ASCO, Abstract #270, 1999.

“A Phase II Trial of Weekly Taxol (T), 5-Fluorouracil (FU) and Leucovorin (LV) Regimen in Patients (PTS) with Metastatic Breast Cancer: An Update. D. Loesch, N.Robvert, S.Dakhill, G.Gusfey, J. Hopkins, T. Rohrbaugh, American Oncology Resources, Houston, TS, USA. Poster, ASCO, Abstract#445, 1999.

“A Phase II Trial of Weekly Tazotere (T), 5-Fluorouracil (FU), and Leucovorin (LV) in Patients with Advanced Breast Cancer”. N.Robert, D. Loesch, S.Dakhil, M. Lee, T. rohrbaugh, American Oncology Resources, Houston, TX, USA. Poster, ASCO, Abstract#451, 1999.

“Phase II Study In Recurrent Breast Cancer with Liposome Encapsulated Doxorubicin”. Treat, J., Greenspan, A., Forst, D., and Rahman, A. Abstract, 11th Annual San Antonio Breast Cancer Symposium, 1988.

“Elliptinlum: Phase II Study in Advanced Measurable Breast Cancer”.Treat, J., Greenspan, A., Byrne, P. (Accepted for Publication, Investigational New Drugs).

Cancer Treatment Toxicity:

“The Incidence of Radiation Pneumonitis as related to the Central Lung Distance in Treatment Planning”—Poster presentation, Radiological Society of America, Chicago, 2002. Minor, GI. Published in “Radiology”, 12/02, abstract only

Chemotherapy drugs:

“Liposome Encapsulated Doxorubicin: Preliminary Results of Phase I and Phase II Trials”. Treat, J., Greenspan, A.R., Rahman, A.: Liposomes In Therapy of Infectious Diseases and Cancer. Vol. 89. Ed. G. Lopez-Bernstein and I. Fidler, Publishers Alan R. Liss, Inc., N.Y. (Accepted for Publication, American Journal of Clinical Oncology, 1988).

“Peripheral Neuropathy and Low Dose Cisplatinum”. Greenspan, A., Treat, J. (Accepted for Publication, American Journal of Clinical Oncology, 1988).

“Phrenic Nerve Paralysis Secondary to Taxol Therapy”. Rhodes, Greenspan et al: (Submitted to Journal of Clinical Oncology).

“Pharmacokinetics of ametantrone acetate (NSC-287513)”. Kuhn, J.G., C.E. Balmer, T.M. Ludden, D.M. Loesch, D.D. Von Hoff, J.F. Bender, and A.J. Grillo-Lopez. Cancer Chemotherapy and Pharmacology, 19: 133-137, 1987.

“Phase I investigation of 1,4-Bis((2(2Hydroxzethylamino)ethyl)amino)-9, 10 anthracenedione diacetate(NSC-287513, Amentantrone Acetate)”. Loesch, D.M., D.D. von Hoff, J. Kuhn, C.A. Coltman, Jr., T. Ludden, J.F.,Bender, A.J. Grillo-Lopez. Cancer Treatment Reports, 67(11): 987-991, 1983.

“Prospective Cardiac Monitoring in Patients Receiving Ametantrone Acetate in a Phase I Trial”. D.D.Von Hoff, D.M. Loesch, J. Kuhn, J.F. Bender, A.J. Grillo-Lopez. Abstract, AFCR (American Federation of Clinical Research) 1983.

“New Anticancer Drugs (Section I Chapter 8)”. Kuhn, J.G., J.W. Meyers, S.K. Callahan, G.R. Gross, D.M. Loesch, and D.D. Von Hoff. Chapter In: Cancer Chemotherapy. ED., H.M. Pinedo. Amsterdam-Oxford: Excerpta Medica, 1982.

“High Performance Liquid Chromatographic Analysis of Ametantrone(CI-881, NSC-287513)”. C.E. McManus, J.G.Kuhn, T.Ludden, D.M.Loesch, D.D.Von Hoff, D. Gordon, C.A. Coltman,Jr., A.J. Grillo-Lopez, and J.Bender. Abstract, ASCO 1982.

“Phase I Investigation of 1,4-Bis(2(20Hydroxyethylamino)ethyl)amino)-9, 10 anthracenedione diacetate (NSC-287513, Amentantrone Acetate)”. David M. Loesch, D.D. Von Hoff, J. Kuhn, C.A. Coltman, Jr., T. Ludden, V. Rodriquez, J.F. Bender, and A.J. Grillo-Lopez. Abstract, ASCO 1982.

Gastrointestinal Cancer

“A Phase II Study of Unresectable Pancreatic Cancer Treated With 5-FU and Leucovorin with Radiation Therapy”. Picus J, Dickerson G, Logie K, Ansari R, Markham R, Spiridonidis C. Submitted for publication.

“Response to the combination of thalidomide and capecitabine as second-line therapy in pancreatic carcinoma after treatment and failure with gemcitabine.” Beganovic S., Loesch D. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 14150

“Continuous Infusion 5-Fluorouracil, Adriamycin, Mitomycin and Cisplatin (FAMP) for Metastatic Gastric Carcinoma”. Raschko, J., Gray, R., Rothschild, N., Warren, R., Ueno, W., Greenspan, A., Woolley, P., and Treat, J. Abstract, Proc. Amer. Soc. Clin. Onc., 1988.

“Cloning of Gastrointestinal Cancer”. Loesch, D.M. and D.D. Von Hoff. Chapter In: Gastrointestinal Cancer. Ed., Bernard Levin and Robert Riddell. New York: Elsevier, 1983.

“Methyl-glyoxal Bisquanylhydrazone (MGBG, Methyl-GAG) in advanced colon cancer: A Phase II trial of the Southwest Oncology Group”. Knight III, W., D.M. Loesch, and C.A. Coltman, Jr.. Cancer Treatment Reports, 66(12); 2099-2100, 1982.

“Direct Cloning of Human Adenocarcinoma of the Colon in Soft Agar: Relationship to Duke’s Stage at the Time of Diagnosis and Degree of Differentiation”. David M. Loesch, D.D.Von Hoff, and the SouthTexas Cloning Group. Abstract, Tuscon Cloning Conference, January 1982.

“Direct Cloning of Human Adenocarcinoma of the Colon in Soft Agar: Relationship to Negative Clinical Correlates and Level of CEA Titer”. David M. Loesch, D.D. Von Hoff, C.P. Page, V. Rodriques, and the South Texas Cloning Group. Abstract, AACR 1982.

“Direct Cloning of Human Adenocarcinoma of the Colon in Soft Agar: Relationship to Duke’s Stage at Time of Diagnosis and Degree of Differentiation.” David M.Loesch, Daniel D. Von Hoff and the South Texas Cloning Group. Poster, Tucson Cloning Conference, January ,1982.

“Direct Cloning of Human Adenocrcinoma of the Colon in Soft Agar: Relationship t Negative Clinical Correlates and Level of CEA Titer.” David M. Loesch, Daniel D. Von Hoff, Carey P. Page, Victorio Rodriguez and the South Texas Cloning Group. Poster, AACR, 1982.

General Medical / Oncology

“How to Create Your Own Computerized Questionnaires”, Marvin Miller and Morgan Tharp; pp 115 – 124 in Mental Health Computing, eds. Marvin J. Miller, Kenric W. Hammond, and Matthew G. Hile. Springer-Verlag, 1996.

“NF-?B Activation Of p53: A Potential Mechanism for Suppressing Cell Growth in Response to Stress.” Wu, H and G. Lozano (1994) Journal of Biological Chemistry 269, 20067-20074.

“The Tumor Suppresser p53 Regulates Its Own Transactivation.” Wu*, H., Deffie, A., Reinke, V. and G. Lozano (1993) Molecular and Cellular Biology 13, 3415-3423 (*Co-First Authors).

“Transcriptional Autoregulation by the Tumor Suppresser p53.” Wu, H., A. Deffie, V. Reinke, and G. Lozano. Presented at The Annual Keystone Symposium on Transcription: Factors, Regulation, and Differentiation, January 1993.

“The relationship of dermatomyositis to underlying malignancy”. Hwang, J.K. The Guthrie Journal, 60:101, 1991.

“Transcriptional Activation By Wild-Type But Not Transforming Mutants Of The p53 Anti-Oncogene.” Raycroft, L., Wu, H. and G. Lozano (1990) Science 249, 1049-1051.

“Transcriptional Activation By Wild-Type But Not Transforming Mutants Of The p53 Anti-Oncogene.” Wu, H., L. Raycroft, and G. Lozano. Presented at Six Annual Meeting on Oncogenes, June 1990.

“The erythrocyte Sedimentation Rate”. Beganovic S. Ann Intern Med 1987: 107: 425

“Removal of a knotted flow-directed catheter by a non-surgical method”. Kumar, S.P., J.Yans, M. Kwatra, D.M. Loesch, V. Viturawong. Annuals of Internal Medicine, 92(5): 639-640, 1980.

“An outbreak of infections caused by strains of Staphylococcus Aureas Resistant to Methicillin and Aminoglycosides I”. Crossley, K., D. Loesch, B. Landesman, K. Meade, M. Hern, and R. Strate. Journal of Infectious Diseases, 139(13): 272-279, 1979.

“Adult Onset Still’s Disease Presenting as F.U.O”. M.S. Murali. Canadian Family Physicians, Volume 24, page 1203, November 1978.

Genitourinary

“Prostate High Dose Rate Brachytherapy in a Free-Standing Cancer Center Setting”, Tharp M, Bennett R, Burns J, et al. Accepted to American Journal of Clinical Oncology March 2007, publication pending.

“Phase II study of low-dose docetaxel/estramustine in elderly patients or patients aged 18-74 years with hormone-refractory prostate cancer”.
Chittoor S, Berry W, Loesch D, Logie K, Fleagle J, Mull S, Boehm KA, Zhan F, Asmar L. Clin Genitourin Cancer. 2006 Dec;5(3):212-8. PMID: 17239275 [PubMed - in process] javascript:top.pmid(‘17239275′); javascript:top.pmid(‘17239275′); US Oncology Research, Inc, Houston, TX, USA. sreeni.chittoor@usoncology.com.

“Phase II Randomized Trial of Weekly Paclitaxel With or without Estramustine Phosphate in Patients with Symptomatic, Metastatic Hormone-Refractory Prostate Cancer (HRPC)”. William Berry, James Hathorn, Shaker Dakhil, David Loesch, Don Jackson, Mary Ann Gregurich, Jennier K. Newcomb-Fernandez, and Lina Asmar, US ONCOLOGY, Houston TX (Submitted for publication.)

“Phase II study of low dose (weekly) docetaxel and estramustine in elderly males (age ?75 years) with hormone-refractory prostate cancer or subjects age 18 to 74 years with an ECOG performance status of 2 or 3”. Chittoor S, Berry W, Loesch D, Logie K, Fleagle J, Mull S, Boehm KA, Zhan F, Asmar L. US Oncology Research, Inc. Presented and Abstract accepted to the ASCO Annual Meeting, 2005.

“NFkB Expression in Prostate Cancer: Tissue Array Analysis from RTOG 86-10”. Hardacre MC, Dicker A, Cheng L, Sweeney C Research 2003.

“A Phase II Study of Altretramine for the Treatment of Metastatic Renal Cell Carcinoma: A Hoosier Oncology Group (HOG) and Walther Cancer Institute Trial”. Picus J, Loehrer P, Logie KW, Ansari R, Mitchell E, Reynolds R, Capizzi R. Abstract accepted to the ASCO Annual Meeting, May 14th – 17th, 1994, Dallas Texas.

Gynecologic
“Concurrent Chemoradiation for Cervical Cancer: Toxicity Profile of Women Treated Off Protocol”. Hardacre MC, McKnight EJ, Eckert G, Moore DH, Randall ME,
Cardenes HR. Int J Radiat Oncol Biol Phys 2001; 51 (3) S1: 217. Presented at the American Society for Therapeutic Radiology and Oncology 43rd Annual Meeting, November 2001.

“Complications Associated with Intraperitoneal P-32,” Tharp M, Hornback N. Gynecologic Oncology, (53), 170-175, 1994.

Head and Neck Cancer

“Verrucous Carcinoma of the Head and Neck Treated with Radiotherapy,”
Tharp M, Shidnia H. Laryngoscope, (105), No. 4, 391-396, April 1995.

Lung Cancer

“Results of a Phase II Trial of Gemcitabine in Patients with Non-Small-Cell Lung Cancer and a Performance Status of 2”. M.A. Neubauer, C.H. Reynolds, M.G. Joppert, T.L. Whittaker, H. Ghaddar, T.A. Marsland,
L.Asmar. Clinical Lung Cancer. Vol. 6, No. 4, 245-249. 2005.

“The impact of Dose per Cycle of Etoposide and Cisplatin on Outcomes in Patients with Extensive Small-Cell Lung Cancer”. Niell HB, Beganovic S et al. Clinical Lung Cancer, Vol. 5, No.5, 299-302, 2004

“Meta-analysis of dose/cycle of etoposide (VP-16) and cisplatin (DDP) and outcome of patients with extensive small cell lung cancer (SCLC). “ Beganovic S,. Niell H. B, S. Richey, J. Wan. Proc Am Soc Clin Oncol 2003 ;22: 662, (abstr 2662)

“Phase II comparative study of two dose schedules of Gemcitabine (Gem) as second-line therapy in patients with advanced non-small cell lung cancer (ANSCLC)”. D.H. Garfield MD, N.J. Robert MD, T.L. Whittaker MD. 8th Int. Congress on Anti-Cancer Treatment. Abstract 104, 1998.

“A Phase II Study of Daily Oral VP16 plus Ifosfamide plus Cisplatin (po ViP) for Previously Treated Recurrent Small Cell Carcinoma of the LUNG (SCLC): A Hoosier Oncology Group (HOG) and Walther Cancer Institute Trial”. Sandler A, Loehrer PJ, Ansari R, Logie KW, Mortimer J, Sridhar R, Einhorn LH. Abstract & Poster accepted to the ASCO Annual Meeting, May 14th – 17th, 1994 Dallas, Texas.

“Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer”. Saxman S, Loehrer PJ Sr, Logie K, Stephens D, Workman F, Scullin D, Einhorn LH, Ansari R. Invest New Drugs. 1991 Aug;9(3):253-6. Indiana University, Department of Medicine, Indianapolis. PMID: 1664423 [PubMed - indexed for MEDLINE]

“Phase II Trial of Daily Oral Etoposide in Patients with Surgically Unresectable Non-Small Cell Lung Cancer”. Saxman S, Logie K, Stephens D, Workman F, Scullin D, Loehrer PJ. Abstract, Proc Am Soc Clin Oncol 9:142, 1990.

Lymphoma / Leukemia / Hematology
“Pegylated liposomal doxorubicin as single-agent treatment of low-grade non-Hodgkin’s lymphoma: a phase II multicenter study”. Di Bella NJ, Khan MM, Dakhil SR, Logie KW, Marsland TA, Weinstein RE, Mirabel MY, Asmar L. US Oncology, Inc., Houston, TX, USA. nicholas.dibella@usoncology.com
Clin Lymphoma. 2003 Mar; 3(4):235-40. PMID: 12672273 [PubMed - indexed for MEDLINE] javascript:top.pmid(‘12672273′); javascript:top.pmid(‘12672273′);

“Relapse and transformation of follicular lymphoma: Prognostic factors and effect on survival.” Wu, HH, Hagemeister, FB, Hess, M., et al. Presented at 8th International Conference on Malignant Lymphoma, June 2002

“Transformation of follicular lymphoma: prognostic factors and effect on survival.” Wu, HH, Hagemeister, FB, Hess, M., et al. Presented at 38th Annual Meeting of ASCO, May 2002.

“Multiple myeloma”. Beganovic S. Djulbegovic B. In Decision Making in Oncology, Churchill Livingstone New York 1997 p.p. 103-112.

“Waldenstroms’s macroglobulinemia.” Beganovic S. Djulbegovic B. In Decision Making in Oncology, Churchill Livingstone New York 1997 p.p. 112-113.

“Precesso Decisionale in Ematologia”. Benjamin Djulbegovic, Sead Beganovic, Roger Herzig, Fred Hendler, and Geetha Joseph. II Centro Scientifico Editore Torino 1994. Italy.

“NonHodgkin’s Lymphomas: Treatment”. Djulbegovic B, Hendler F, Beganovic S. In Benjamin Djulbegovic, Sead Beganovic, Roger Herzig, Reasoning and Decision of Making in Hematology. Churchill Livingstone New York 1992 pp 151-155.

“Hodgkin’s Disease”. Djulbegovic B, Hendler F, Beganovic S. In Benjamin Djulbegovic, Sead Beganovic, Roger Herzig, Reasoning and Decision of Making in Hematology. Churchill Livingstone New York 1992 pp 157-160.

“Lymphomas: Diagnostic Workup”. Djulbegovic B, Hendler F, Beganovic S. In Benjamin Djulbegovic, Sead Beganovic, Roger Herzig, Reasoning and Decision of Making in Hematology. Churchill Livingstone New York 1992 pp151-155.

“Multiple myeloma”. Djulbegovic B, Hendler F, Beganovic S. In Benjamin Djulbegovic, Sead Beganovic, Roger Herzig, Reasoning and Decision of Making in Hematology. Churchill Livingstone New York 1992 pp 177-180.

“Porphyrias: Diagnosis”. Beganovic S. Djulbegovic B. In Benjamin Djulbegovic, Sead Beganovic, Roger Herzig, Reasoning and Decision of Making in Hematology.Churchill Livingstone New York 1992 p.p. 67-69.

“Porphyrias: Treatment”. Beganovic S. Djulbegovic B. In Benjamin Djulbegovic, Sead Beganovic, Roger Herzig, Reasoning and Decision Making in Hematology. Churchill Livingstone New York 1992 pp 71-73.

“Lymphadenopathy: Diagnostic Approach”. Beganovic S. Djulbegovic B. In Benjamin Djulbegovic, Sead Beganovic, Roger Herzig, Reasoning and Decision of Making in Hematology. Churchill Livingstone New York 1992 p.p. 143-146.

“Splenomegaly as a Dominant Clinical Feature: Diagnostic Approach”. Djulbegovic B, Beganovic S. In Benjamin Djulbegovic, Sead Beganovic, Roger Herzig, Reasoning and Decision of Making in Hematology. Churchill Livingstone New York 1992 pp147-150.

“Red Blood Cells and Platelet Transfusion”. Djulbegovic B, Beganovic S . In Benjamin Djulbegovic, Sead Beganovic, Roger Herzig, Reasoning and Decision of Making in Hematology. Churchill Livingstone New York 1992 pp 239-242.

“Transfusion reactions”. Djulbegovic B, Beganovic S. In Benjamin Djulbegovic, Sead Beganovic, Roger Herzig, Reasoning and Decision of Making in Hematology. Churchill Livingstone New York 1992 pp 243-246.

“Hyperbilirubinemia”. Beganovic S. Djulbegovic B . In Benjamin Djulbegovic, Sead Beganovic, Roger Herzig, Reasoning and Decision of Making in Hematology. Churchill Livingstone New York 1992 pp 75-77.

“Predictive value of lactate dehydrogenase (LDH) as a plausible tumor marker in Hematology/Oncology”. Beganovic S., JergovicD. Robovic X. Bull Hematol Trans 1990; 17:01 -19.

“Prophylactic platelet transfusion in Hematology and Oncology”. Beganovic S., Robovic Z., Nikolic J. , Bull Hematol Trans 1988; 16:5.23.

“Optimal timing for bone marrow transplantation in chronic granulocytic leukemia”. Djulbegovic B., Denic S., RidjanovicZ. Beganovic S. Bull Hematol Trans 1988; 16:4.5

“Prophylactic platelet transfusion in Hematology and Oncology”. Beganovic S., Robovic Z., Nikolic J., Bull Hematol Trans 1988; 16:5.23.

“Approach to the patient with hemolytic anemia: Potentials and limitations of clinical algorithm”. Beganovic S., Obradov S., Jergovic D. Bull Hematol Trans 1988; 16:10.7.
“Hemorrhoidectomy in a Hemophiliac with Factor VIII Inhibitors”. M.S. Murali. Indiana Medicine, Vol. 80:332, 1987.

“DIC in Chronic Myelogenous Leukemia with Chloromas, and Sea Blue Histiocytosis”. M.S. Murali. Clinical Research, Volume 20, 1972.

Radiation / Radiobiology:
“Parthenolide Induced Radiosensitivity in CGL1 Cell Lines”. Hardacre MC, Mendonca M Presented at American Society for Therapeutic Radiology and Oncology 45 th Annual Meeting, October 2003.

Skin:
“Phase II study of daily oral VP-16 in metastatic melanoma: A Hoosier Oncology Group study”. T.L. Whittaker MD, L.H. Einhorn MD. Proceedings of the American Society of Clinical Oncology. Abstract 1198, 1992.